Reynders Mc Veigh Capital Management, LLC Seagen Inc. Transaction History

Reynders Mc Veigh Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$191.51 - $216.16 $114,331 - $129,047	-597 Reduced 16.65%	2,988 $634,000
Q2 2023 Aug 09, 2023	SELL	$187.64 - $206.25 $24,393 - $26,812	-130 Reduced 3.5%	3,585 $690,000
Q1 2023 May 03, 2023	SELL	$127.59 - $203.08 $65,070 - $103,570	-510 Reduced 12.07%	3,715 $752,000
Q4 2022 Feb 10, 2023	SELL	$117.37 - $139.17 $18,192 - $21,571	-155 Reduced 3.54%	4,225 $543,000
Q1 2022 May 11, 2022	BUY	$119.61 - $157.85 $23,922 - $31,570	200 Added 4.78%	4,380 $631,000

Q4 2021 Feb 11, 2022	SELL	$142.57 - $190.86 $28,656 - $38,362	-201 Reduced 4.59%	4,180 $646,000
Q3 2021 Nov 15, 2021	SELL	$142.45 - $169.82 $150,997 - $180,009	-1,060 Reduced 19.48%	4,381 $744,000
Q2 2021 Aug 12, 2021	SELL	$135.08 - $161.1 $40,524 - $48,330	-300 Reduced 5.23%	5,441 $859,000
Q1 2021 May 07, 2021	SELL	$137.51 - $190.8 $147,135 - $204,156	-1,070 Reduced 15.71%	5,741 $797,000
Q4 2020 Feb 10, 2021	BUY	$164.63 - $211.93 $1.12 Million - $1.44 Million	6,811 New	6,811 $1.19 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Reynders Mc Veigh Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Reynders Mc Veigh Capital Management, LLC with notifications on news.